(5-Aminosalicylic acid) from enemas and suppositories during steady-state conditions. Scand J gastroenterol 1991; 26: 374-84. Dew MJ, Hughers pJ, Lee MG, Rhodes J: An oral preparation to release drugs in the human colon. Br J Clin Pharmacol 1982; 14: 405-85. Marshall JK, Irvine EJ: Putting rectal 5-Aminosalicylic acid in its place: the role in distal ulcerative colitis. Am J Gastroenterol 2000; 95: 1628-366. Bondesen S, Rasmussen SN, Rask-Madsen J, Nielsen OH, Lauritse K, Binder V, Hansen SH, Hvidberg EF: 5-Aminosalicylic acid in the treatment of inflammatory bowel disease. Acta Med Scand 1987; 221: 227-427. Caprilli R, Frieri G, Latella G: Isalicilati nella terapia delle malattie infiammatorie intestinali. Raven Health Care Communications, New York, 1993.8. Riley SA: What dose of 5-aminosalicylic acid (masalazine) in ulcerative colitis Gut 1998; 42: 761-39. De Vos M: Clinic Pharmacokynetic of prolonged released mesalazine. Clin Pharmacokinet 2000; 39(2): 85-9710. Campieri M, Lanfranchi GA, Boschi S, Brignola C, Bazzocchi G, gionchetti P, Minguzzi MR, Belluzzi a, Lab_ G: Topical administration of 5-aminosalicilyc acid enemas in patients with ulcerative colitis. Studies on rectal absorption and excretion Gut 1985; 26: 400-511. Frieri G, Giacomelli R, Pimpo M, Palumbo G, Passacantando A, Pantaleoni G, Caprilli R: Mucosal 5-Aminosalicylic acid concentration inversely corelates with severity of colonic inflammation in patients with ulcerative colitis. Gut 2000; 47: 410-1412. Gibson PR, Jewell DP: Sulphasalazine and derivates, natural killer activity and ulcerative colitis. Clin Sci 1985; 69: 177-8413. Allgayer H, Stenson WF: A comparison of effects of sulphasalazine and its metabolites on the methabolism of endogenous vs exogenous arachidonic acid. Immunopharmacology 1988; 15: 39-4614. Nielsen OH, Bouchelouche PN, Berild D: Effects of 5-aminosalicylic acid and analogous substances on superoxide generation and intracellular free calcium in human neutrophilic granulocytes. Scand J Gastroenterol 1993; 28:527-3215. Pullman WE, Doe WF: IL-2 production by intestinal lamina propria cells in normal inflamed and cancer-bearing colons Clin Exp Immunol 1992; 88: 132-716. Bissonette EY, Enciso JA, dean befus AD: Inhibitory effects of sulphasalazine and its metabolites on histamine release and TN-alpha production by mast cells. J Immunol 1996; 156: 218-2317. Kaiser GC, Yan F, Polk DB: Mesalamine blocks Tumor necrosis factor growth inhibition and nuclear facto kB activation in mouse colonocytes. Gastroenterology 1999; 116: 602-918. Crotty B, Hoang P, Dalton HR: Salicylates used in inflammatory bowel disease and colchicines impair interferon-gamma induced HLA-DR expression. Gut 1992; 33: 59-6419. Frieri G, Pimpo MT, Palumbo G, Tonelli F, Annese V, Sturniolo GC, Andreoli A, Comberlato M, Corrao G, Capilli R and GISC: Anastomotic configuration and mucosal 5-Aminosalicylic acid (5-ASA) concentrations in patients with Crohn\'s disease: a GISC study. Am J Gastroenterol 2000; 96(6) 1486-9020. Hebden JM, Blackshaw PE, Perkins AC, Wilson CG, Spiller RC: Limited exposure of the healthy distal colon to orally-dosed formulation is further exaggerated in active left-sided ulcerative colitis. Aliment pharamcol Ther 2000; 14: 155-6121. DeVos M, Verdievel H, Shoonjans R, Praet M, Bogaert M, Barbier F: Concentrations of 5-ASA and Ac-5-ASA in human ileocolonic biopsy homogenates after oral 5-ASA preparations. Gut 1992; 33: 1338-4222. Hussain F, AJJan R, Trugdill N : Dose loading with oral mesalazine-optimising drug concentration in the mucosa (abs) Gastroenterology 1996; Apr 110 (Suppl): A92823. Frieri G, Pimpo MT, Palumbo GC, Onori L, Viscido A, Latella G, Galletti B, Pantaleoni GC, Caprilli R: rectal and colonic mesalazine concentration in ulcerative colitis: oral vs oral plus topical treatment. Aliment Pharmacol Ther 1999; 13: 1413-1724. Shah S, Peppercorn MA: A comparative review of topical therapies for inflammatory bowel disease. Clin Immunother 1996; Aug 6(2): 117-2525. Cohen R, Woseth DM, Thisted RA, Hanauer SB: A Meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol 2000; 95: 1263-7626. Hanauer SB: Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multicente placebo-controlled trial. Infl Bowel Dis 1998; 4(2): 79-8327. Travis SPL, Tysk C, de Silva HJ, Sandbrg-Gertzðn H, Jewell DP; Janerot G: Optimum dose of olsalazine for maintaining remission in ulcerative colitis Gut 1994; 35: 1282-8628. Pimpo MT, Frieri G, Galletti B, Latella G, Chiaramonte M, Caprilli R: DDW Atlanta 2001
